ライフサイエンスコーパス: serious

1 s were mostly mild or moderate and none were serious.

2 res careful matching of blood types to avoid serious adverse consequences.

3 No vaccine-related serious adverse effects were found in the dose-ranging s

4 6 [1 = difficult, 5 = easy]) and was without serious adverse effects.

5 4%) in the control group reported at least 1 serious adverse event (adjusted RR, 1.72 [95% CI, 0.7 to

6 rse events (OR 2.65, 95% CI: 1.04-6.80), any serious adverse event (OR 2.30, 95% CI: 1.18-4.48), seri

7 One serious adverse event (SAE) that resulted in death was p

8 At least 1 serious adverse event developed in 12 patients (24%) in

9 Peri-prosthetic joint infections (PJI) are a serious adverse event following joint replacement surger

10 icipants randomised to rosuvastatin, and one serious adverse event in each group.

11 Pneumonia was the only serious adverse event in more than 2% of patients (seven

12 One 3-year-old patient had a serious adverse event of accidental ribavirin overdose r

13 Serious adverse event rates could not be determined with

14 l outcome data at week 16-17, or sooner if a serious adverse event requiring knowledge of the study d

15 At least one treatment-related serious adverse event was reported in 25 (10%) patients

16 25 (42%) patients reported at least one serious adverse event, which most commonly was an infect

17 was well tolerated, with a low incidence of serious adverse events (16%).

18 43.9% [43/98] vs 25.5% [25/98]; P = .01) and serious adverse events (27.6% [27/98] vs 12.2% [12/98];

19 Few participants in either group had serious adverse events (3 [2.4%] vs. 5 [4.0%]).

20 Serious adverse events (AEs) occurred in 10% of imipenem

21 No serious adverse events (AEs) related to treatment were r

22 PVR) is associated with a risk of procedural serious adverse events (SAE) and exposure to ionizing ra

23 The total incidence of AE and serious adverse events (SAE) was calculated.

24 Within clinical trials, rates of systemic serious adverse events (SAEs) after anti-VEGF treatment

25 ment outcomes, culture-conversion rates, and serious adverse events (SAEs) during treatment.

26 nth 36 in part 1, and symptomatic dengue and serious adverse events (SAEs) up to Month 36 in both par

27 Endpoints were solicited/unsolicited and serious adverse events (SAEs), biochemical/hematological

28 te the existing evidence for serious and non-serious adverse events after ivermectin exposure in preg

29 amounts, reduce time to recovery, and reduce serious adverse events among hospitalized patients not r

30 years in the placebo group; the incidence of serious adverse events and adverse events leading to wit

31 sivir probably improves recovery and reduces serious adverse events and may reduce mortality and time

32 There were no drug-related serious adverse events and no treatment-related deaths.

33 No serious adverse events attributed to ruxolitinib were ob

34 7 mothers in the dolutegravir group reported serious adverse events compared with 14 (11%) of 131 in

35 ssociated with an increased risk of death or serious adverse events compared with allopurinol.

36 30%) in the placebo group (with 6 infectious serious adverse events developing among 4 patients [9%])

37 te nomograms to calculate the probability of serious adverse events during OFC for individual patient

38 tment-emergent adverse events, including six serious adverse events in five patients and 13 discontin

39 Serious adverse events in the lower-threshold group incl

40 Serious adverse events included 1 suicide attempt, relat

41 The outcomes of these serious adverse events included 16 deaths, 4 of which we

42 regimen was safe, with no treatment-related serious adverse events observed.

43 No related serious adverse events occurred during the second year.

44 Three serious adverse events occurred during the study (pulmon

45 Serious adverse events occurred equally between groups.

46 Serious adverse events occurred in 10% of participants o

47 Serious adverse events occurred in 115 (34%) patients in

48 Nonfatal serious adverse events occurred in 12/72 (16.7%) in the

49 Serious adverse events occurred in 22.7% and 21.7%, resp

50 Treatment-related serious adverse events occurred in 25 (24%) patients and

51 Serious adverse events occurred in 250 (45%) of 559 pati

52 Serious adverse events occurred in 33 (10%) of 332 patie

53 Serious adverse events occurred in 7.2% of patients in t

54 All 14 serious adverse events occurred in patients who received

55 Treatment-related serious adverse events occurred in seven (12%) patients

56 Treatment-related serious adverse events occurred in six (14%) of 42 patie

57 Three serious adverse events occurred in the biomechanical foo

58 No intervention-related serious adverse events occurred, and few adverse effects

59 Four non-DBS-related serious adverse events occurred, including one suicide a

60 %) in the rituximab group (with 9 infectious serious adverse events occurring among 6 patients [12%])

61 No vaccine-related serious adverse events or severe dengue virus disease we

62 adverse event (OR 2.30, 95% CI: 1.18-4.48), serious adverse events related to abnormal liver functio

63 not differ significantly between the groups; serious adverse events related to rhythm-control therapy

64 gs and are associated with increased risk of serious adverse events such as infusion reactions and an

65 Of the 16 serious adverse events unrelated to the study drugs, 4 (

66 Serious adverse events up to week 24 occurred in no pati

67 CI 232.71-243.57) per 100 patient-years and serious adverse events was 12.63 (95% CI 11.41-13.94) pe

68 The incidence of serious adverse events was low and was similar in the va

69 p difference in the incidence or severity of serious adverse events was reported during the follow-up

70 The number of serious adverse events was similar in both groups and un

71 The frequency of serious adverse events was similar in the two groups.

72 Serious adverse events were assessed in all women who re

73 No serious adverse events were attributed to dihydroartemis

74 3.94) per 100 patient-years; the most common serious adverse events were infections at 4.13 (95% CI 3

75 The most common serious adverse events were lower respiratory tract infe

76 Adverse events and serious adverse events were minimal, but 2 deaths (7.4%)

77 Serious adverse events were more common with systematic

78 Serious adverse events were observed in ten (28%) patien

79 The most common serious adverse events were pyrexia (n=9), pneumonia (n=

80 Serious adverse events were recorded in 30 and 40 patien

81 No serious adverse events were related to vaccination.

82 Two serious adverse events were reported - both resolved wit

83 Serious adverse events were reported for 18 (20%) of 90

84 Serious adverse events were reported for 18 (8%) patient

85 Any-cause serious adverse events were reported in 121 (45%) patien

86 Serious adverse events were reported in 4 (3%), 5 (3%),

87 Serious adverse events were reported in 84 of 182 patien

88 Serious adverse events were reported in five (3%) of 156

89 Eight serious adverse events were reported with capsular relea

90 Serious adverse events were similar between groups (112

91 Serious adverse events were similar in both groups (vita

92 Cumulative rates of serious adverse events were similar in TAK-003 (4.0%) an

93 tinence, daily cigarette consumption change, serious adverse events, adverse events, dropouts due to

94 dose, including solicited adverse events and serious adverse events, and immunogenicity (seroprotecti

95 rare, with generally no group differences in serious adverse events, any adverse events, hospitalizat

96 rimary safety outcome (a composite of death, serious adverse events, or clinical grade 3 or 4 adverse

97 36 individuals had 63 serious adverse events, which included 25 suicide attemp

98 c drugs on cardiac contractility can lead to serious adverse events.

99 All subjects completed the study without any serious adverse events.

100 s limited, it indicated no increased risk of serious adverse events.

101 sion at week 12 but was associated with more serious adverse events.

102 lement for MPOD volume and SC levels without serious adverse events.

103 ences of malaria, vaso-occlusive crises, and serious adverse events.

104 lar numbers of donor-specific antibodies and serious adverse events.

105 and safety, as measured by the occurrence of serious adverse events.

106 There were no intervention-related serious adverse events.

107 no significant between-group differences in serious adverse events.

108 erventional management, with a lower risk of serious adverse events.

109 ere no clinically relevant treatment-related serious adverse events.

110 rly after two of the four patients developed serious adverse events.

111 , and 5 (3.3%) vs 9 (6.1%) experienced other serious adverse events.

112 acute and chronic exposure to OPs can cause serious adverse health effects.

113 participants in the PRESERVE (Prevention of Serious Adverse Outcomes Following Angiography) trial wi

114 erize the relative risk for and incidence of serious adverse outcomes following the development of CA

115 17 serious adverse reactions occurred in 11 patients, and t

116 than with placebo (40.1% vs. 16.8%), but no serious adverse reactions were reported.

117 mes included cumulative incidence rates for (serious) adverse events.

118 ssociated with an increased relative risk of serious, adverse 90-day outcomes, the incidence of clini

119 The evidence for dupilumab-related serious AE is uncertain.

120 Serious AEs (n = 20; 48%) included infections (n = 14) a

121 Further, there were no ocular serious AEs (SAEs) and no cases of endophthalmitis.

122 Treatment was well tolerated in most however serious AEs can occur in those with advanced liver disea

123 There were no serious AEs in any of the study arms.

124 nd polyneuropathy (n = 2); treatment-related serious AEs included 2 grade 3 polyneuropathies and 1 gr

125 Two additional serious AEs were reported (rhinitis [JNJ-8678]; pneumoni

126 systemic events (SEs), adverse events (AEs), serious AEs, newly diagnosed chronic medical conditions,

127 There were no serious AEs.

128 Three (1.2%) patients had 12 serious AEs; most were cardiac disorders; all were unrel

129 Retinal detachment (RD) is a serious and common condition, but genetic studies to dat

130 , and the associated health consequences are serious and costly.

131 en the groups was shown in the occurrence of serious and drug-related adverse events.

132 The therapy led to serious and life-threatening toxic effects that were con

133 aimed to evaluate the existing evidence for serious and non-serious adverse events after ivermectin

134 egions as well as asymptomatic infections, a serious barrier to eliminating this disease.

135 ithout compromising hemostasis, thus causing serious bleeding and increased morbidity and mortality.

136 mbosis in humanized mice, but neither causes serious bleeding, establishing a causal link between par

137 primary outcome of death, disabling stroke, serious bleeding, or cardiac arrest.

138 nd derived structure distortion would induce serious capacity loss and voltage decay, further hinderi

139 Strategies to prevent serious cardiac complications in this high-risk cohort o

140 bjectives were to determine the incidence of serious cardiac events (SCEs) in pregnant women with hea

141 d compared the rates of the composite of all serious cardiovascular events (MI, stroke, coronary reva

142 edian of 3.7 years of follow-up, 3,417 total serious cardiovascular events occurred in 2,003 individu

143 Canakinumab reduced the rates of total serious cardiovascular events, with rates per 100 person

144 s trialled in COVID-19 are unlikely to cause serious cardiovascular toxicity.

145 coronaviruses are not yet approved, posing a serious challenge to current global efforts aimed at con

146 tion of such complex forms of big data poses serious challenges to users of MD.

147 metastasis and resistance to therapy remain serious clinical challenges.

148 terpretative value and that there is often a serious collinearity issue for the gene-level models whi

149 s had an estimate 28-68% increased odds of a serious complication and a 58-60% increased odds of 30-d

150 Cytomegalovirus (CMV) infection is a serious complication in immunosuppressed patients, speci

151 nusoidal obstruction syndrome (VOD/SOS) is a serious complication post allogeneic hematopoietic stem

152 es, acute kidney injury (AKI) is a frequent, serious complication ranging from 10% to 30%.

153 th the lowest risk- and reliability-adjusted serious complication rates for each operation.

154 r discriminating any complication, 0.523 for serious complication, and 0.559 for readmission.

155 must be assessed on all radiographs because serious complications can arise if catheters are malposi

156 Serious complications requiring reoperation or producing

157 No serious complications such as blindness, anaphylactic re

158 tension, diabetes mellitus, and obesity, and serious complications such as stroke and heart failure.

159 Serious complications were predominantly cardiac and ass

160 Serious complications were significantly associated with

161 likely has no effect on severe desaturation, serious complications, apneic time, oxygenation, ICU len

162 sumption of contaminated crops is becoming a serious concern for human health.

163 Gut bacteria-associated sepsis is a serious concern in patients with gastrointestinal acute

164 is an infrequent but morbid and potentially serious condition associated with antiresorptive and ant

165 formation accounts for the etiology of many serious conditions including myocardial infarction, stro

166 ther, these findings highlight a potentially serious confound in prior work, raising new theoretical

167 Increasing air pollution in South Asia has serious consequences for air quality and human/ecosystem

168 his work establishes organic polaritons as a serious contender to the well-established GaAs platform

169 sing levels of antimicrobial resistance pose serious dangers to patients, population health, food sec

170 ndently associated with death or persistent, serious deterioration of health-related quality of life

171 improve the quality of life of children with serious disease and increase support for their parents a

172 ich is the causative agent of melioidosis, a serious disease that occurs in the tropics, and a potent

173 olating selected vibrational modes, leads to serious drawbacks for interrogation of the trapped phono

174 Ground deformation can cause serious environmental issues such as infrastructure dama

175 Anthraquinone dyes pose a serious environmental problem as their reinforced struct

176 ics and the access to cheap oil, is creating serious environmental problems.

177 Resident physicians made more serious errors during the intervention schedules than du

178 es that eliminated extended shifts made more serious errors than resident physicians assigned to sche

179 The number of serious errors unitwide were likewise higher during the

180 Severe acute malnutrition (SAM) is the most serious form of undernutrition, characterized by wasting

181 g tool to tackle antimicrobial resistance, a serious global health problem.

182 SARS-CoV-2 infection has emerged as a serious global pandemic.

183 -related outcomes, with little to no risk of serious harm.

184 Influenza B virus is a serious health concern for children, in particular, yet

185 olyfluoroalkyl substances (PFAS), which pose serious health concerns.

186 Many individuals with serious health problems were experiencing significant pa

187 The serious health problems, recent healthcare experiences,

188 Eating raw oysters can come with serious health risks, as oysters can potentially contain

189 e and liver are associated with a variety of serious health risks.

190 les associated with death and/or persistent, serious health-related quality of life deterioration wer

191 otransporter 2 inhibitors reduce the risk of serious heart failure and adverse renal events, but the

192 ied in a patient with Tetralogy of Fallot, a serious heart valve defect, affects the substrate select

193 Major depressive disorder (MDD) is a serious, heterogeneous disorder accompanied by brain-rel

194 Inflammation is associated with a range of serious human conditions, including autoimmune and cardi

195 s central to the etiology of a wide range of serious human diseases, such as Alzheimer's disease and

196 ising advances to aid rural people to manage serious illness and to die in place.

197 n how to have meaningful conversations about serious illness using telecommunication.

198 k response was resource intensive and caused serious illness, particularly among unvaccinated childre

199 es that address the needs of all people with serious illness-related suffering and their caregivers.

200 ation of programs to alleviate the burden of serious illness-related suffering in these settings.

201 e proven benefits of nonhospice PC for other serious illnesses and cancer, there are no evidence-base

202 tic care at an early stage for patients with serious illnesses and their families is commonly referre

203 roperly evaluated as there can be underlying serious illnesses as in our patient.

204 teria, protozoa, and viruses, that can cause serious illnesses.

205 ion, this study demonstrates the potentially serious impact of introducing thinner, more flexible tis

206 visuospatial function domains were the most serious impaired domains in the major cognitive impairme

207 vior and are at a particularly high risk for serious impairment relative to others with these disorde

208 Our findings have serious implications for the management of PCB contamina

209 e to false-positive dengue serology can have serious implications.

210 ls, principally in order to minimize risk of serious infection.

211 However, recent trends for IE and other serious infections among persons with substance use diso

212 Rates of hospitalization for serious infections among persons with SUDs are increasin

213 Neutropenia and neutrophil dysfunction cause serious infections and inflammatory bowel disease in gly

214 is a gram-positive organism responsible for serious infections in humans, but as with many bacterial

215 on, and charges between hospitalizations for serious infections in patients with and without OUD.

216 In addition, the detection of serious infections may be more challenging owing to pati

217 Serious infections occurred in 2.5% and 1.8% of the pati

218 use disorder (OUD) who are hospitalized for serious infections requiring prolonged intravenous antib

219 oups had higher incidences of infections and serious infections vs placebo.

220 d no difference between groups in pneumonia, serious infections, any infection, hemorrhage, renal fai

221 rium of antifungals available to treat these serious infections.

222 tment may be feasible and safe for PWID with serious infections.

223 s; no guselkumab-treated patient died or had serious infections.

224 of 427 patients in the adalimumab group had serious infections.

225 group died from cardiac failure and two had serious infections; no guselkumab-treated patient died o

226 city score; sinusoidal obstruction syndrome; serious infections; WHO Bleeding Scale; transfusion requ

227 %) patients under active treatment developed serious infectious events, and two (10%) developed diver

228 virgifera (Coleoptera: Chrysomelidae), is a serious insect pest in the major corn growing areas of N

229 ed wing drosophila, Drosophila suzukii, is a serious invasive pest impacting the production of multip

230 g number of published articles can present a serious issue for both trainees and senior scientists al

231 l time-of-flight (TOF) MSI continues to be a serious issue.

232 by the SARS-CoV-2 has recently emerged as a serious jolt to human life and economy.

233 white-light emission properties, they pose a serious long-term environmental and health risk as they

234 y higher than use of systemic treatments for serious manifestations of the disease and diagnosis of l

235 ensure safety for patients being treated for serious methicillin-resistant Staphylococcus aureus infe

236 The overall rates of death or serious morbidity (DSM) and clinically-relevant fistula

237 be less effective than believed at reducing serious morbidity and mortality in this population, whic

238 Serious morbidity composite was significantly lower in p

239 ure to COVID-19 had increased probability of serious morbidity, healthcare seeking, hospitalization,

240 Vancomycin is used to treat serious MRSA infections, but treatment failures occur de

241 ts management is a major challenge given the serious nature of the thrombotic disease observed, which

242 this particular experiment to highlight the serious need to consider the frame of reference of the e

243 synthetic polymeric materials that can pose serious negative environmental impacts, cellulose-based

244 of nanomaterials-based formulations to avoid serious neurotoxic complications, which may further lead

245 ug-resistant strains of this bacterium cause serious nosocomial infections and are the leading cause

246 priority" pathogen which is a major cause of serious nosocomial infections such as bacteremia, sepsis

247 quared) of 40 or higher or 35 or higher with serious obesity-related comorbidities.

248 ment, waste of administrative resources, and serious obstacles to wildlife protection.

249 Serious obstetric events were also examined.

250 Both SARS-CoV and MERS-CoV have caused serious outbreaks and epidemics in the past eighteen yea

251 ts aged >=65 years were admitted to Canadian Serious Outcomes Surveillance Network hospitals during t

252 This silly sentence makes a serious point: As humans, we can flexibly generate and c

253 lable, some recent publications illustrate a serious potential failing in this domain: inclusion of r

254 sensitivity of these assays can represent a serious problem if the occurrence of experimental errors

255 Malnutrition is a serious problem in the elderly while understanding flavo

256 fections after a craniotomy (SSI-CRAN) are a serious problem involving significant morbidity and cost

257 This method suffers from a serious problem: The resulting ratios are highly correla

258 OSCL and CL of gas are more serious problems due to the risk of long-term leakage fr

259 Serious procedure-related adverse events were uncommon.

260 stigating the relationship between sleep and serious psychological distress (SPD) have lacked racial/

261 hand exposure to e-cig aerosols has become a serious public health concern.

262 rticulate matter (PM) pollution has become a serious public health issue, especially with outbreaks o

263 eria is of critical importance in addressing serious public health problems.

264 emonstrate convincing evidence that BoV is a serious respiratory pathogen.

265 ly intake calculation, samples do not pose a serious risk to public health.

266 cause of congenital birth defects, and poses serious risks for immuno-compromised individuals.

267 nt concern in maize production, as they pose serious risks to human and animal health.

268 This poses a serious roadblock for clinical translation of this appro

269 sign was observational, 21 of 36 studies had serious ROB, and publication bias was possible.

270 However, use of CsA is associated with more serious side effects and worse clinical outcomes than FK

271 DEBs eliminates the need for stents so that serious side effects including in-stent restenosis and s

272 rials to treat metabolic syndrome due to the serious side effects such as hypertriglyceridemia and al

273 when initiated early in illness but can have serious side effects.

274 ration may improve outcomes in patients with serious streptococcal infections.

275 Enterococcus faecalis, long implicated in serious systemic infections and failure of root canal tr

276 The frequency of serious TEAEs was similar between the groups (10% in the

277 All serious TEAEs were unrelated to treatment.

278 There are serious theoretical problems with the free-energy princi

279 ins, such as aflatoxin B(1) (AFB(1)), pose a serious threat as biological weapons due to their high t

280 These prime cases epitomize the serious threat that wildlife poisoning poses to biodiver

281 obally, and drug-resistant TB strains pose a serious threat to controlling the global TB epidemic.

282 Antimicrobial resistance is a serious threat to human health worldwide, prompting rese

283 I) is a devastating disease of poultry and a serious threat to public health.

284 viruses, are emerging pathogens that pose a serious threat to public health.

285 Such knowledge is needed to thwart serious threats to human health and calls to mind the pr

286 Enterovirus 71 (EV71) poses serious threats to human health, particularly in Southea

287 Serious treatment-emergent adverse events in more than o

288 Serious treatment-emergent adverse events occurred in 93

289 No drug-related serious treatment-emergent adverse events occurred.

290 Serious treatment-related adverse events occurred in 11

291 Serious treatment-related adverse events occurred in 30

292 The most common serious treatment-related adverse events were nervous sy

293 Serious treatment-related adverse events were reported i

294 14 (9%) patients had serious treatment-related adverse events, most commonly

295 15 (11%) patients had serious treatment-related adverse events, the most commo

296 Five (9%) patients had serious treatment-related adverse events.

297 re opportunistic infections in patients with serious underlying medical conditions, such as those wit

298 , and the ability of opioid drugs to produce serious undesired effects has been recognized for a simi

299 ar after vaccination with PCV20 or PCV13; no serious vaccine-related AEs were reported.

300 antaviruses are rodent-borne viruses causing serious zoonotic outbreaks worldwide for which no treatm